SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that Damien McDevitt, Ph.D., has joined
ACADIA as Senior Vice President, Corporate Development, leading the
company’s corporate development activities. He will report to Steve
Davis, ACADIA’s President and Chief Executive Officer.
This press release features multimedia. View the full release here:
Damien McDevitt, Ph.D., Senior Vice President, Corporate Development (Photo: Business Wire)
“We are thrilled to welcome Damien to the team,” said Steve Davis.
“Damien has extensive experience in business development, licensing and
strategic partnering, and he has completed dozens of value-creating
transactions. This expertise, combined with his strong strategic and
technical background, will be of great value as we continue to explore
the potential for expanding our CNS portfolio.”
Dr. McDevitt joins ACADIA after more than two decades at GlaxoSmithKline
plc, where he was at the forefront of the R&D externalization effort,
and involved in more than 70 global business development transactions
spanning a variety of therapeutic areas, including neuroscience. Most
recently, he was Vice President, Head of Business Development for R&D
Extended Therapy Areas, Head of Worldwide Business Development Asia, and
head of the company’s R&D West Coast Satellite. Prior to that, Dr.
McDevitt held positions with increasing responsibility within Worldwide
Business Development, GSK Ventures and Anti-Infectives Discovery. Dr.
McDevitt attended Trinity College in Dublin, Ireland, where he earned
his Ph.D. and his undergraduate degree, both in Microbiology. He is an
author of 70 scientific publications and published patents.
ACADIA also announced that Jim Nash, Senior Vice President, Technology
Development and Operations, will be retiring from the company as of
January 2018. Bob Mischler, formerly Senior Vice President, Strategy and
Business Development, will assume responsibilities for technology
development and operations in addition to continuing his strategy
responsibilities in the new role of Senior Vice President, Strategy and
“We thank Jim for his significant contributions over the past several
years,” said Mr. Davis. “Under his leadership, ACADIA expanded its
manufacturing, pharmaceutical development and GMP quality assurance
operations, all of which were critical to the approval and
commercialization of NUPLAZID. We wish Jim well in his retirement.”
About NUPLAZID® (pimavanserin)
is the first and only FDA-approved treatment for hallucinations and
delusions associated with Parkinson’s disease psychosis (PD Psychosis).
NUPLAZID is a non-dopaminergic, selective serotonin inverse agonist
preferentially targeting 5-HT2A receptors that are thought to
play an important role in PD Psychosis. NUPLAZID is an oral medicine
taken once a day with a recommended dose of 34 mg (two 17-mg tablets).
ACADIA discovered this new chemical entity and holds worldwide rights to
develop and commercialize NUPLAZID.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to the benefits to be derived from NUPLAZID (pimavanserin) and
the potential expansion of ACADIA’s CNS portfolio. These statements are
only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or results
may differ materially from those projected in any of such statements due
to various factors, including the risks and uncertainties inherent in
drug discovery, development, approval, and commercialization, and the
fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2016 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
Important Safety Information and Indication for
NUPLAZID (pimavanserin) tablets
MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. NUPLAZID is not approved for
the treatment of patients with dementia-related psychosis unrelated to
the hallucinations and delusions associated with Parkinson’s disease
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
Contraindication: NUPLAZID is contraindicated in patients with a history
of a hypersensitivity reaction to pimavanserin or any of its components.
Rash, urticaria, and reactions consistent with angioedema (e.g., tongue
swelling, circumoral edema, throat tightness, and dyspnea) have been
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2%
for NUPLAZID and greater than placebo) were peripheral edema (7%
vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination
(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole)
increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half.
Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced
efficacy. Increase in NUPLAZID dosage may be needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in
patients with mild to moderate renal impairment. Use of NUPLAZID is not
recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in patients with
hepatic impairment. NUPLAZID has not been evaluated in this patient
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and
should therefore be used in pregnancy only if the potential benefit
justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in
Dosage and Administration: Recommended dose: 34 mg per day, taken orally
as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning,
please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005273/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.